Fig. 4: Inflammatory response after BPX-601 may be predictive of grades 3–4 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) after rimiducid in patients with mCRPC. | Nature Communications

Fig. 4: Inflammatory response after BPX-601 may be predictive of grades 3–4 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) after rimiducid in patients with mCRPC.

From: PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial

Fig. 4

a Radar graph showing peak cytokine/chemokine response after BPX-601 cell infusion grouped per maximal CRS or ICANS grade after rimiducid. Increases in circulating levels of a constellation of inflammatory markers after BPX-601 infusion were significantly higher in patients who later experienced grades 3–4 CRS or ICANS after the first or second rimiducid infusion, compared to patients who experienced no or grade 1 CRS or ICANS after rimiducid infusion. Radar graph shows minimum, mean, and maximum level for each marker in the patient group. b Levels of IL-6 after BPX-601 administration were significantly elevated in the three patients with mCRPC who experienced grade ≥3 CRS or ICANS after the first or second dose of rimiducid (shown in red) compared to patients who experienced a maximum of grade 1 CRS or ICANS (shown in black). * indicates the two patients with carHLH who died during the study. Timeline (days) has been adjusted to align BP-601 and rimiducid infusions across all patients. Rim rimiducid. Source data are provided as a Source Data file.

Back to article page